Mitosol

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerPancreatic CancerColorectal CancerHepatocellular CarcinomaGastric CancerMetastatic Colorectal CancerLung CancerBladder CancerEsophageal CancerAdenocarcinomaNasopharyngeal CarcinomaLiver CancerUrothelial CarcinomaGlaucomaColorectal CarcinomaUrinary Bladder CancerMesotheliomaMyopiaColorectal NeoplasmSclerosing CholangitisTransitional Cell CarcinomaOpen-Angle GlaucomaPterygiumChronic Renal Failure SyndromeKeratoconusLung NeoplasmUrinary Bladder CarcinomaBladder TumorAnal CarcinomaPseudomyxoma PeritoneiMetastatic Malignant NeoplasmUrethral StrictureBladder Urothelial CarcinomaMuscle-Invasive Bladder CarcinomaAnal Basaloid CarcinomaNon-Muscle Invasive Bladder Urothelial CarcinomaAnus CancerAppendix CancerCorneal DiseaseAnal Squamous Cell Carcinoma, Limited-StageIn Situ Carcinoma

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

Mitosol

UUroGen Pharma Ltd.

Approved

372

Halaven

Eisai

Preclinical

383

Prolia

Amgen

Preclinical

144

Blenoxane

Bristol-Myers Squibb

Preclinical

15

Zolymbus

AbbVie

Preclinical

16

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

37

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

38

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

19

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

110

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1Show 6 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Bladder Cancer9 trials

Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

Completed·Radiation Therapy Oncology Group·Phase 2·NCT00981656·37 enrolled

BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

Active, not recruiting·NNottingham University Hospitals NHS Trust·Phase 3·NCT06462001·500 enrolled

Sequential Combination Therapy in Bladder Cancer

Unknown status·AAzienda Ospedaliera "Sant'Andrea"·Phase 4·NCT03790384·140 enrolled

Show 6 more trials

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Recruiting·NNRG Oncology·Phase 3·NCT07097142·486 enrolled

Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer

Unknown status·UUniversity of Sydney·Phase 3·NCT02948543·501 enrolled

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04216290·95 enrolled

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Completed·MMayo Clinic·Phase 2·NCT03617913·2 enrolled

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Recruiting·MMayo Clinic·Phase 1/2·NCT06704191·40 enrolled

Guidance of Adjuvant Instillation in Intermediate Risk Non-muscle Invasive Bladder Cancer by Drug Screens in Patient Derived Organoids. A Single Center, Open-label, Phase II Trial With a Feasibility Endpoint. (GAIN-INST-TRIAL)

Active, not recruiting·RRoland Seiler-Blarer·Phase 2·NCT05024734·31 enrolled

Hepatocellular Carcinoma3 trials

The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma

Withdrawn·SSeoul National University Hospital·Phase 2·NCT01953406

Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma

Terminated·SSeoul National University Hospital·Phase 2·NCT01171482·5 enrolled

Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma

Unknown status·SSecond Military Medical University·Phase 1/2·NCT02638857·60 enrolled

Gastric Cancer2 trials

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Recruiting·—·Phase 1·NCT04329494·49 enrolled

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

Recruiting·UUniversity of Chicago·Phase 2·NCT04107077·21 enrolled

Liver Cancer2 trials

Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003907·50 enrolled

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT01004978·235 enrolled

Colorectal Cancer2 trials

Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy

Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT04845490·201 enrolled

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

Not yet recruiting·—·Phase 3·NCT07271355·129 enrolled

19 more indications

Glaucoma1 trial

Lucentis Versus Mitomycin C During Glaucoma Surgery

Completed·WWills Eye·Phase 2/3·NCT00626782·24 enrolled

Solid Tumors1 trial

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01017640·20 enrolled

Anal Cancer1 trial

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04929028·40 enrolled

Efficacy and Safety1 trial

Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy.

Completed·MMedical University of Lublin·Phase 1·NCT03766425·64 enrolled

Fluorouracil1 trial

A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer

Terminated·—·Phase 1/2·NCT01671488·11 enrolled

LAM1 trial

Automated Lamellar Keratectomy in Symptomatic Patients With Bullous Keratopathy

Completed·FFederal University of São Paulo·N/A·NCT00654888·28 enrolled

Locally Advanced Colon Cancer1 trial

Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer

Not yet recruiting·MMaimónides Biomedical Research Institute of Córdoba·Phase 3·NCT06783491·1,083 enrolled

Neoadjuvant1 trial

Precise Neoadjuvant Chemoresection of Low Grade NMIBC

Not yet recruiting·UUniversity of Bern·Phase 2·NCT06227065·28 enrolled

Esophageal Cancer1 trial

Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02891447·24 enrolled

Phase II1 trial

Phase II Trial of Lung Chemoemobolization

Recruiting·—·Phase 2·NCT05672108·30 enrolled

Lung Cancer1 trial

Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.

Completed·AAktion Bronchialkarzinom e.V.·Phase 3·NCT00148395·280 enrolled

Intensity-modulated Radiotherapy1 trial

Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal

Terminated·—·Phase 2·NCT01843452·8 enrolled

Colorectal Carcinoma1 trial

Prophylactic Surgery Plus HIPEC With CO2 in Patients Affected by Colorectal Carcinoma. CHECK Study.

Unknown status·Mario Negri Institute for Pharmacological Research·N/A·NCT03914820·330 enrolled

Bladder Urothelial Carcinoma1 trial

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT03775265·475 enrolled

Anal Basaloid Carcinoma1 trial

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

Active, not recruiting·EECOG-ACRIN Cancer Research Group·Phase 2·NCT04166318·252 enrolled

Anal Squamous Cell Carcinoma, Limited-stage1 trial

A Multicenter, Phase III, Randomized Controlled Clinical Trial of Sintilimab Versus Mitomycin in Combination With Capecitabine and Intensity-Modulated Radiotherapy in the Treatment of Limited-stage Anal Squamous Cell Carcinoma

Recruiting·CCancer Institute and Hospital, Chinese Academy of Medical Sciences·Phase 3·NCT07692152·350 enrolled

Non-Muscle Invasive Bladder Urothelial Carcinoma1 trial

Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06770582·160 enrolled

Muscle-Invasive Bladder Carcinoma1 trial

Consolidative Radiation Therapy or Cystectomy After Initial Favorable Response Succeeding Enfortumab Vedotin Plus Pembrolizumab (REINFORCE)--- A Phase I/II Pilot Feasibility Trial

Not yet recruiting·UUniversity of Washington·Preclinical·NCT07579195·12 enrolled

Unspecified1 trial

Conjunctival Vascularity Changes Usnig OCTA After Trabeculectomy

Unknown status·AAsmaa Ahmed Ali Youssif·Phase 1·NCT04493073·100 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Patent Landscape[5]

Related News